Henry Schein (HSIC)
(Delayed Data from NSDQ)
$73.31 USD
-0.13 (-0.18%)
Updated May 10, 2024 04:00 PM ET
After-Market: $73.31 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
HSIC 73.31 -0.13(-0.18%)
Will HSIC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HSIC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HSIC
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
HSIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Henry Schein (HSIC) Q1 Earnings
Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View
Henry Schein (HSIC) Surpasses Q1 Earnings Estimates
Other News for HSIC
Henry Schein (HSIC) Holds Steady Amid Market Challenges: A Balanced Analyst Perspective
Expert Outlook: Henry Schein Through The Eyes Of 7 Analysts
Analysts Have Conflicting Sentiments on These Healthcare Companies: Henry Schein (HSIC) and Esperion (ESPR)
Henry Schein price target raised by $2 at Barrington, here's why
Henry Schein Sell Rating Affirmed Amidst Cybersecurity Woes and Execution Risks